The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Q2 2025 Earnings Call Transcript July 16, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...

Synovitis is significantly more likely among patients with psoriasis, and it is more likely among those with PsA than PsO.

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

B oth men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)-a chronic inflammatory ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

Lyme disease is a complex condition with a long history of misdiagnosis, and Lyme arthritis, a late manifestation of the ...

In psoriatic arthritis, results from the POETYK PsA-1 and POETYK PsA-2 trials are supporting the company's filings.